

Letter to the Editor

Epithelial barrier dysfunction in desmoglein-1 deficiency

To the Editor:

Mutations in the desmoplakin (*DSP*) and desmoglein-1 (*DSG1*) genes have been implicated in patients with the inherited inflammatory skin disease known as severe dermatitis, multiple allergies, and metabolic wasting (SAM) syndrome (MIM#603165, see [Tables E1](#) and [E2](#) in this article's Online Repository at www.jacionline.org).^{1,2} The *DSP* and *DSG1* genes encode desmosome components that are critical for the structure of intercellular junctions and maintenance of epithelial barrier integrity. *DSP* and *DSG1* are also key regulators of signaling pathways involved in differentiation, epidermal homeostasis, and carcinogenesis. *DSG1* promotes keratinocyte differentiation by inhibiting epidermal growth factor receptor/extracellular signal-regulated kinase signaling through ERBB2-interacting protein (ERBIN), a scaffolding and signaling protein.³ Through characterization of a new syndrome featuring severe allergic dermatitis and *DSG1* deficiency, we highlighted the pivotal role of the functional *DSG1*/ERBIN interaction as an inhibitor of skin inflammation through the nuclear factor κ B (NF- κ B) signaling pathway.

Patients 1 and 2 (13 and 9 years old, respectively) are 2 unrelated boys born to healthy parents. They were referred for life-long desquamative erythroderma associated with sparse and wooly hair and dysplastic enamel. Both patients had painful palmoplantar keratoderma and dystrophic nails ([Fig 1, A and B](#)). Skin manifestations combined recurrent and painful erythrodermic skin flares triggered by infections and episodes of aseptic pustular psoriasiform dermatitis. Patient 1 (but not patient 2) displayed failure to thrive, eosinophilic esophagitis, colitis, and a variety of food allergies (total serum IgE level, 2968 kIU/mL [$n < 114$]). Cardiac examination of patient 1 revealed an asymptomatic, biventricular, dilated cardiomyopathy. At 9 years of age, patient 2 received a heart transplant because of a severe left-dominant arrhythmogenic cardiomyopathy.

For both patients, cutaneous histopathology showed epidermal acantholysis and dermal inflammatory lymphocytic infiltration ([Fig 1, C](#), and see [Fig E1](#) and the [Methods](#) section in this article's Online Repository at www.jacionline.org). Ultrastructural examination revealed large numbers of abnormal clusters of desmosomes in the epidermis (patient 1; [Fig 1, D](#)). Histopathology of the explanted heart showed the characteristic fibro-fatty myocardial infiltration of arrhythmogenic dysplasia (see [Fig E1](#)).

Two different heterozygous *de novo* missense mutations were identified by using whole-exome sequencing in exon 14 of the *DSP* gene: c.A1757C (p.H586P, patient 1) and c.T1828C (p.S610P, patient 2). Substitution of H586 or S610 by a proline is expected to induce a kink in the α -helix of DSP plakin domain that perturbs *DSP*'s 3-dimensional structure (see [Fig E1](#)).

In both patients skin immunohistochemistry showed the following features: (1) low *DSP* and *DSG1* expression in the epidermis (as in patient 1's primary keratinocytes), (2) irregular and less intense *DSP* and *DSG1* staining at the keratinocyte plasma membrane, and (3) abnormal cytoplasmic accumulation of *DSP* and *DSG1* proteins in keratinocytes ([Fig 1, E](#)). Esophageal

immunohistochemistry revealed a low level of *DSP* staining, which was irregular and mottled at the cell border, and the absence of *DSG1* expression (patient 1; [Fig 1, F](#)). Expression of *DSP* protein was also low in heart tissue (patient 2; see [Fig E1](#); *DSG1* is not expressed in the heart).

Abnormally high levels of mRNAs encoding proinflammatory cytokines (*IL6*, *IL8*, and *IL1B*), 3 NF- κ B target genes, and *TSLP* were found in patient 1's keratinocytes ([Fig 2, A](#)). Overexpression of *IL-6* was confirmed by means of ELISA (see [Fig E2](#) in this article's Online Repository at www.jacionline.org). In contrast, mRNA levels of *TNFA* and other pro-T_H2 cytokines (*IL13*, *CCL5*, and *IL4*; data not shown) were not increased. Inhibition of the NF- κ B signaling pathway by ML120B, which selectively targets the catalytic subunit of inhibitor of NF- κ B kinase (IKK) β , restored normal expression of *IL8* mRNA by patient 1's keratinocytes (see [Fig E2](#)). In view of the primary *DSG1* deficiency reported in patients with SAM syndrome and the very low levels of *DSG1* protein expression in our patients, we hypothesized that *DSG1* could play a role in the inflammatory phenotype. We demonstrated that *DSG1* (but not *DSP*) inhibits NF- κ B reporter activity in a dose-dependent manner after stimulation by IL-1 β or TNF- α in HEK293T cells ([Fig 2, B](#), and see [Fig E2](#)). Concomitant downregulation of *IL6* and *IL8* expression was observed on transfection with the *DSG1*-encoding plasmid (see [Fig E2](#)). Silencing of *DSG1* by short hairpin RNA (with a mean decrease of *DSG1* mRNA of 32%) enhanced transcription of *IL6*, *IL8*, *IL1B*, *TNFA*, and *TSLP* genes in control keratinocytes (regardless of stimulation with IL-1 β ; [Fig 2, C](#), and see [Fig E2](#)). Retroviral transduction of wild-type *DSG1* into patient 1's keratinocytes rescued the inflammatory cellular phenotype by restoring *IL8* production ([Fig 2, D](#)).

Given that *DSG1* might regulate ERBIN's cellular localization and thus modulate the latter's ability to block extracellular signal-regulated kinase signaling, we hypothesized that ERBIN can play a role in *DSG1*-mediated NF- κ B inhibition.³ We observed little ERBIN/*DSG1* colocalization at the cell membrane and an accumulation of ERBIN in the cytoplasm in a skin biopsy specimen from patient 1 relative to healthy control values (mean proportion of ERBIN/*DSG1* colocalization, 40.7% vs 71.2%; $P < .001$; see [Fig E3](#) in this article's Online Repository at www.jacionline.org).

Experiments in control keratinocytes highlighted recruitment of ERBIN to the cell membrane and an increase in ERBIN/*DSG1* colocalization after stimulation by IL-1 β . Interestingly, this recruitment did not occur in patient 1's keratinocytes (see [Fig E3](#)). Contrary to patient 1's keratinocytes, the level of ERBIN protein increased after stimulation of control keratinocytes by IL-1 β (see [Fig E3](#)). These results demonstrated that localization of ERBIN at the cell membrane and membrane colocalization of ERBIN/*DSG1* in keratinocytes were regulated by inflammatory stimuli (eg, IL-1 β).

In a reporter transactivation assay, we found that ERBIN transfection in both nonstimulated and IL-1 β -stimulated HEK293T cells led to NF- κ B activation in a dose-dependent manner ([Fig 2, E](#)). *Erbin*^{-/-} keratinocytes, derived from *Erbin*^{-/-} mice, showed abnormally low mRNA expression of the proinflammatory cytokines *IL6* and *IL1B* ([Fig 2, F](#)). In addition, abnormally low expression of *IL1B* mRNA were found in the *Erbin*^{-/-} mouse




FIG 1. Clinical and histopathologic features of patients 1 and 2. **A**, Clinical phenotype of patient 1: desquamative erythroderma, thickening of the skin (*a-e*), sparse hair (*a*), diffuse palmoplantar keratoderma (PPK; *b* and *c*), and thickening of the nail plate (*d* and *e*). **B**, Clinical phenotype of patient 2: desquamative erythroderma (*a*), sparse hair (*a* and *b*), onycholysis (*c*), and plantar keratoderma (*d*). **C**, Skin histology (patient 1) showing epidermal acanthosis, hyperorthokeratosis, extensive acantholysis (*inset*), and inflammation in the superficial dermis (lymphocytes; $\times 100$ magnification for Fig 1, *C*, and $\times 200$ magnification for the *inset* of Fig 1, *C*). **D**, Ultrastructural features of a skin biopsy specimen from patient 1 (*a*, *b*, and *d*) and a healthy control subject (*c*). *a*, Many desmosomes clustered in the upper epidermis (*arrows*). Keratin filaments strongly aggregated to the desmosome (*inset*). *b*, Complete absence of desmosomes and widened spaces between keratinocytes (cell membrane features filipodium-like processes; *inset*) in the lower epidermis. *d*, Patient 1's desmosome lacks the inner plaque compared with a control subject (*arrow*, *c*). Scale bar = $2\ \mu\text{m}$ for Fig 1, *D*, *a* and *b*. Scale bar = $500\ \text{nm}$ for the *inset* of Fig 1, *D*, *a* and $1\ \mu\text{m}$ for the *inset* of Fig 1, *D*, *b*. **E**, Immunofluorescence on skin sections from a healthy control subject (*a-c*), patient 1 (*d-f*), and patient 2 (*g-i*) showed drastic reduction and mislocalization in staining of DSP and DSG1 in both patients. Scale bar = $20\ \mu\text{m}$. **F**, Immunofluorescence on esophageal sections from a healthy control subject (*a-c*) and patient 1 (*d-f*), showing low levels of DSP staining and absence of DSG1 staining in patient 1. Scale bar = $20\ \mu\text{m}$.




FIG 2. Role of DSG1 and ERBIN in NF-κB-mediated epithelial inflammation. **A**, Relative mRNA expression levels of proinflammatory cytokines in primary keratinocytes (patient 1). **B**, NF-κB luciferase reporter assay in HEK293T cells transfected with DSG1 vector or with an empty vector and stimulated with IL-1β or TNF-α. AU, Arbitrary units. *Inset*, Western blot of DSG1 expression in HEK293T cells transfected with DSG1 vector. **C**, Relative mRNA expression of *IL8* (*a*), *IL6* (*b*), *IL1B* (*c*), *TNFA* (*d*), and *TSLP* (*e*) in control (*ctrl*) keratinocytes infected with a lentivirus-expressing short hairpin RNA against *DSG1* and stimulated or not stimulated (*NS*) with IL-1β. **D**, Relative mRNA expression of patient 1's keratinocytes infected with a retrovirus expressing FLAG *DSG1*. *Inset*, Western blot of DSG1 and FLAG expression in patient 1's keratinocytes after transduction. **E**, NF-κB luciferase reporter assay in HEK293T cells transfected with ERBIN or empty vector and stimulated with IL-1β. *Inset*, Western blot of ERBIN expression in HEK293T cells transfected with the ERBIN vector. **F**, Relative mRNA expression levels of *IL1B* and *IL6* in nonstimulated *Erbin*^{+/+} and *Erbin*^{-/-} keratinocytes. **G**, Relative mRNA expression levels of *IL1B* in *Erbin*^{+/+} and *Erbin*^{-/-} MEFs before/after stimulation with LPS. **H**, Immunoblot assays showing degradation of IκBα proteins in *Erbin*^{+/+} and *Erbin*^{-/-} MEFs induced by IL-1β stimulation. **P* < .05, ***P* < .01, and ****P* < .001.

embryo fibroblasts (MEFs), regardless of stimulation with LPS (Fig 2, G). Biochemical analysis of NF- κ B activation showed that in *Erbin*^{-/-} MEFs, I κ B α degradation was delayed in response to IL-1 β (Fig 2, H).

Here we report on 2 unrelated patients in whom severe dermatitis and loss of epithelial barrier integrity were related to 2 different heterozygous mutations in *DSP*. Both patients presented with a combination of SAM syndrome, ectodermal dysplasia (combination of hair, nail, and tooth anomalies), and arrhythmogenic cardiomyopathy (hereby named SAMEC syndrome). Because of the major risk of severe cardiac involvement in patients carrying a *DSP* mutation, a thorough cardiac assessment should always be carried out in patients presenting with the SAM syndrome phenotype unless *DSP* mutations have been ruled out.

Our results demonstrate that DSG1 inhibits skin inflammation by inhibiting the NF- κ B signaling pathway. Various observations support that DSG1 deficiency is linked to inflammation. First, DSG1 deficiency has been reported in patients with atopic dermatitis and Netherton syndrome,^{4,5} which share chronic inflammatory dermatitis and allergic manifestations with SAMEC. Second, 2 siblings presented with Netherton syndrome and normal DSG1 epidermal staining, whereas no skin inflammation was observed.⁶ Third, DSG1 deficiency is probably responsible for the mucosal barrier impairment and inflammation observed in patients with eosinophilic esophagitis.⁷

We suggest that DSG1 normally inhibits the NF- κ B signaling pathway, at least in part by retaining ERBIN at the cell membrane. Involvement of ERBIN in other inflammatory diseases has been shown. In the context of inflammatory bowel disease, ERBIN seems to specifically inhibit the NF- κ B signaling pathway through nucleotide-binding oligomerization domain 2.⁸ In addition, 5 related patients presenting with allergic inflammatory manifestations similar to SAMEC syndrome (eczema, eosinophilic esophagitis, and an increased serum IgE level) were shown to carry a heterozygous mutation in the gene coding for ERBIN.⁹ Thus ERBIN mislocalization in patients with SAMEC syndrome might explain our patients' allergic manifestations.

Through characterization of SAMEC syndrome, we showed that DSG1 acts as a novel and hitherto unexpected inhibitor of epithelial inflammation by inhibiting the NF- κ B signaling pathway, probably through functional DSG1/ERBIN interaction. The lack of an epithelial barrier protein, here DSG1, appears to be a crucial link between loss of epithelial barrier integrity and immunologic dysregulation.

We thank the families involved in this study and the following physicians for their collaboration: Jean-Jacques Grob (Marseille, France), Véronique Fressart (Paris, France), Estelle Gandjbakhch (Paris, France), and Lionel Fontao (Geneva, Switzerland).

Laura Polivka, MD, MSc^{a,b,*}
Smail Hadj-Rabia, MD, PhD^{a,b,*}
Elodie Bal, PhD^b
Stéphanie Leclerc-Mercier, MD^{a,c}
Marine Madrange, MSc^b
Yamina Hamel, PhD^b
Damien Bonnet, MD, PhD^d
Stéphanie Mallet, MD^e
Hubert Lepidi, MD^f

Caroline Ovaert, MD^g
Patrick Barbet, MD, PhD^c
Christophe Dupont, MD^h
Bénédicte Neven, MD, PhDⁱ
Arnold Munnich, MD, PhD^j
Lisa M. Godsel, PhD^{k,l}
Florence Campeotto, MD, PhD^m
Robert Weil, MD, PhDⁿ
Emmanuel Laplantine, PhDⁿ
Sylvie Marchetto, BS, BM^o
Jean-Paul Borg, PhD^o
William I. Weis, PhD^p
Jean-Laurent Casanova, MD, PhD^{q,r,s,t}
Anne Puel, PhD^{q,r,s,t}
Kathleen J. Green, PhD^{k,l}
Christine Bodemer, MD, PhD^{a,b,*}
Asma Smahi, PhD^{b,*}

From ^athe Department of Dermatology, Reference Center for Genodermatoses (MAGEC), ^bthe Laboratory of Genetics of Monogenic Auto-inflammatory Diseases, Necker Branch, U1163, ^cthe Department of Pathology, ^dM3C-Necker, Pediatric Reference Center for Inherited Cardiac Diseases, ^ethe Department of Pediatric Gastroenterology, Hepatology and Nutrition, ^fthe Department of Pediatric Immunology and Hematology, and ^mthe Department of Paediatric Gastroenterology, Necker-Enfants Malades Hospital (AP-HP), Paris Descartes-Sorbonne Paris Cité University, Imagine Institute, Paris, France; Departments of ^gDermatology, ^hPathology, and ⁱPediatric Cardiology, La Timone Hospital (AP-HM), Aix Marseille University, Marseille, France; ^jthe Laboratory of Molecular and Pathophysiological Basis of Cognitive Disorders, U1163, Paris Descartes-Sorbonne Paris Cité University, Imagine Institute, Necker-Enfants Malades Hospital, Paris, France; the Departments of ^kPathology and ^lDermatology, Northwestern University Feinberg School of Medicine, Chicago, Ill; ⁿthe Laboratory of Signaling and Pathogenesis, Centre National de la Recherche Scientifique, UMR3691, Pasteur Institute, Paris, France; ^oCentre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille University, UM105, Inst Paoli-Calmettes, CNRS, UMR7258, Inserm, U1068, "Cell Polarity, Cell Signaling, and Cancer-Equipe Labellisée Ligue Contre le Cancer," Marseille, France; ^pthe Departments of Structural Biology, Molecular & Cellular Physiology and Photon Science, Stanford University, Stanford, Calif; ^qthe Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Paris, France; ^rParis Descartes University, Imagine Institute, Paris, France; ^sSt Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, Rockefeller University, New York, NY; and ^tthe Howard Hughes Medical Institute, New York, NY. E-mail: christine.bodemer@aphp.fr. Or: asma.smahi@inserm.fr.

*These authors contributed equally to this work.

Supported by grants from the French Society of Dermatology (SFD), Laboratoires Expanscience, and the French National Research Agency (ANR) under the "Investments for the Future" program (reference: ANR-10-IAHU-01). Expanscience Laboratories helped to fund the molecular and immunologic analyses. J.-P.B.'s laboratory is funded by La Ligue Nationale Contre le Cancer (Label Ligue) and SIRIC (INCA-DGOS-Inserm 6038). J.-P.B. is a scholar of Institut Universitaire de France.

Disclosure of potential conflict of interest: J.-L. Casanova reports personal fees from Genentech, Sanofi, Novartis, Pfizer, Bioaster, Regeneron, BiogenIdec, and Merck outside the submitted work. The rest of the authors declare that they have no relevant conflicts of interest.

REFERENCES

- Samuelov L, Sarig O, Harmon RM, Rapaport D, Ishida-Yamamoto A, Isakov O, et al. Desmoglein 1 deficiency results in severe dermatitis, multiple allergies and metabolic wasting. *Nat Genet* 2013;45:1244-8.
- McAleer MA, Pohler E, Smith FJD, Wilson NJ, Cole C, MacGowan S, et al. Severe dermatitis, multiple allergies, and metabolic wasting syndrome caused by a novel mutation in the N-terminal plakin domain of desmoplakin. *J Allergy Clin Immunol* 2015;136:1268-76.
- Harmon RM, Simpson CL, Johnson JL, Koetsier JL, Dubash AD, Najor NA, et al. Desmoglein-1/Erbin interaction suppresses ERK activation to support epidermal differentiation. *J Clin Invest* 2013;123:1556-70.
- Broccardo CJ, Mahaffey S, Schwarz J, Wruck L, David G, Schlievert PM, et al. Comparative proteomic profiling of patients with atopic dermatitis based on history of eczema herpeticum infection and *Staphylococcus aureus* colonization. *J Allergy Clin Immunol* 2011;127:186-93, e1-11.
- Fortugno P, Furio L, Teson M, Berretti M, El Hachem M, Zambruno G, et al. The 420K LEKTI variant alters LEKTI proteolytic activation and results in protease

- deregulation: implications for atopic dermatitis. *Hum Mol Genet* 2012;21:4187-200.
6. Guerra L, Fortugno P, Pedicelli C, Mazzanti C, Proto V, Zambruno G, et al. Ichthyosis linearis circumflexa as the only clinical manifestation of Netherton syndrome. *Acta Derm Venereol* 2015;95:720-4.
 7. Sherrill JD, Ke K, Wu D, Djukic Z, Caldwell JM, Stucke EM, et al. Desmoglein-1 regulates esophageal epithelial barrier function and immune responses in eosinophilic esophagitis. *Mucosal Immunol* 2014;7:718-29.
 8. McDonald C, Chen FF, Ollendorff V, Ogura Y, Marchetto S, Lécine P, et al. A role for Erbin in the regulation of Nod2-dependent NF-kappaB signaling. *J Biol Chem* 2005;280:40301-9.
 9. Lyons JJ, Liu Y, Ma CA, Yu X, O'Connell MP, Lawrence MG, et al. ERBIN deficiency links STAT3 and TGF- β pathway defects with atopy in humans. *J Exp Med* 2017;214:669-80.

<https://doi.org/10.1016/j.jaci.2018.04.007>

METHODS

Molecular genetics

DNA was extracted from peripheral blood lymphocytes by using the Nucleon BACC3 DNA extraction kit (GE Healthcare, Piscataway, NJ), according to the manufacturer's instructions. Samples of genomic DNA (1 μ g) from patient 1 and his parents underwent whole-exome sequencing. The exons were captured with an in-solution enrichment technique (Sure-Select Human All Exon Kits Version 3; Agilent, Massy, France) based on a biotinylated oligonucleotide probe library (Human All Exon v3 50 Mb; Agilent). Each genomic DNA fragment was sequenced by using the paired-end strategy and an average read length of 75 bases (Illumina HiSeq Sequencer; Illumina, San Diego, Calif). Image analysis and base calling were performed with the Illumina Real-Time Analysis pipeline (version 1.9, Illumina) by using its default parameters. Sequences were aligned with the Human Genome Project reference sequence (hg19 assembly), and single nucleotide polymorphisms were called on the basis of allele calls and read depth by using the Consensus Assessment of Sequence and Variation pipeline (version 1.8; Illumina).

Genetic variations were annotated by using an in-house pipeline (IntegratGen, Evry, France), and the results for each sample were made available online for analysis with ERIIS (<http://eris.integratgen.com/>). The *DSP* variant was confirmed by using Sanger sequencing with specific primers for exon 14 of the *DSP* gene. For patient 2 and his relatives, *DSP*'s 24 exons were amplified by using PCR with specific primers. The PCR products were sequenced by using the Sanger method and a BigDye Terminator Cycle Sequencing Ready Reaction Kit (version 3.1; Applied Biosystems, Foster City, Calif) and then analyzed with SeqScape software (version 3.0; Applied Biosystems). Whole-exome sequencing was then performed for patient 2.

Primary keratinocyte culture

Primary human keratinocytes were obtained from 4-mm punch biopsy specimens from patient 1 and 3 healthy control subjects. Keratinocytes were cultured on a feeder layer of lethally irradiated mouse 3T3-J2 fibroblasts, as described previously.^{E1,E2} Perhaps because of intrinsic factors linked to desmosomal disease, several tentative keratinocyte cultures for patient 2 failed. Similarly, keratinocytes from patient 1's biopsy specimen were obtained after several culture assays.

Cell lines

HEK293T cells were purchased from ATCC (Teddington, Middlesex, United Kingdom).

Isolation and culture of MEFs and epidermal keratinocytes from *Erbin*-null mice

Primary MEFs were isolated from 14.5-day-old *Erbin*^{+/+} and *Erbin*^{-/-} FVB mouse embryos. After dissection, fetuses were transferred in sterile PBS, livers and heads were removed and discarded, and the remaining part of each fetus was teased into fine pieces. Tissues were broken up into a suspension by means of vigorous pipetting, and after a short sedimentation, the remaining cell suspension was grown in Dulbecco modified Eagle medium supplemented with 10% FCS and antibiotics.

Primary mouse epidermal keratinocytes were isolated from 19.5-day-old *Erbin*^{+/+} and *Erbin*^{-/-} BALB/c mouse embryos. After dissection, fetuses were transferred in sterile PBS; heads, paws, and tails were removed and discarded; and back skins were removed and treated with Dispase (Gibco/Invitrogen, Carlsbad, Calif). The epidermis was separated from the dermis with forceps and incubated with a trypsin/versene mixture. The epidermis was cut into small pieces, and after pipetting vigorously up and down, the basal layer keratinocytes were separated out from the epidermis. The cell suspension was filtered, washed with medium, and grown in CnT-57 medium (CELLnTEC, Bern, Switzerland) containing a low concentration of bovine pituitary extract.

RNA extraction, RT-PCR, and real-time PCR

Total RNA was isolated from HEK293T cells, MEFs, and cultured keratinocytes from patient 1 and different control subjects by using the RNeasy Plus Mini Kit (Qiagen GmbH, Hilden, Germany), according to the manufacturer's instructions. RNA samples were reverse transcribed into cDNA by using the High Capacity cDNA Reverse Transcriptase Kit (Applied Biosystems). Real-time PCR was carried out with the Fast SYBR Green PCR Master Mix (Applied Biosystems) on an ABI Prism 7000 (PE Applied Biosystems). Quantitative RT-PCR primers were designed by using the sequences available in Ensembl and spanned an intron-exon boundary.

Amounts of the various mRNAs were normalized against the amount of *ACTB* RNA in each sample (measured by using quantitative RT-PCR). Results were analyzed with DataAssist (version 3.01; Applied Biosystems), which uses the comparative cycle threshold (ddCt) method. All experiments were performed in triplicates.

All data are expressed as the means \pm SDs. Values were calculated by using an unpaired *t* test as follows.

Immunoblotting analysis

HEK293T cells were transiently transfected with increasing doses (100–1000 ng) of DSG1 plasmid (plasmid #55029; Addgene, Cambridge, Mass) or 250 ng of DSP plasmid (plasmid #32227; Addgene) and/or ERBIN plasmid (pEF1-Erbin-Myc-HisA construct) together with 0.2 μ g of Ig κ -Luc (see above). Cells were then lysed in RIPA buffer (150 mmol/L NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, and 50 mmol/L Tris-HCl [pH 8]) with protease inhibitors (Roche Diagnostics GmbH, Mannheim, Germany). Western blotting was performed by using mouse anti-DSP I/II antibody (diluted 1:1000, sc-390975; Santa Cruz Biotechnology, Heidelberg, Germany), rabbit anti-DSG1 antibody (diluted 1:1000, sc-20114; Santa Cruz Biotechnology), and rabbit anti-ERBIN antibody (diluted 1:10000, a gift from Lionel Fontao, Laboratory of Dermatology, University Hospitals and Medical School of Geneva, Geneva, Switzerland). Bound antibodies were visualized with horseradish peroxidase-conjugated antibodies against rabbit or mouse IgG (Santa Cruz Biotechnology) and an Enhanced Chemiluminescence kit (SuperSignal West Dura Extended Duration Substrate; Thermo Scientific, Rockford, Ill). Western blotting to assess degradation of I κ B α proteins in MEFs was performed with a mouse anti-I κ B α antibody (diluted 1:1000, L35A5; Cell Signaling Technology, Danvers, Mass). MEFs were stimulated with 20 ng/mL mouse IL-1 β (R&D Systems, Minneapolis, Minn).

Inhibition of IKK-2 by ML120B

Keratinocytes from a healthy control subject and patient 1 were seeded into 12-well plates (100,000 cells/well). Twenty-four hours later, keratinocytes were preincubated with 20 μ mol/L ML120B at 37°C for 1 hour and then stimulated with 10 ng/mL IL-1 β . Twenty-four hours after stimulation, cells were pelleted for RNA extraction. ML120B was sent as a gift by Emmanuel Laplantine (Institut Pasteur, Paris, France).

Luciferase NF- κ B reporter assays

HEK293T cells were seeded into 24-well plates and transfected in triplicates by using jetPRIM reagent (Polyplus Transfection, New York, NY) with increasing doses (100–1000 ng) of DSG1 plasmid (mCherry-desmoglein-1-C-18, a gift from Michael Davidson; plasmid #55029; Addgene) or 250 ng of DSP plasmid (1136-Desmoplakin-GFP, a gift from Kathleen Green (Addgene plasmid #32227) and/or increasing doses (100–500 ng) of ERBIN plasmid (pEF1-Erbin-Myc-HisA construct, a gift from Masaki Inagaki, Division of Biochemistry, Aichi Cancer Center Research Institute, Chikusa-ku, Nagoya, Aichi, Japan), together with 0.2 μ g of a plasmid carrying the firefly luciferase gene under the control of the NF- κ B promoter (Ig κ -Luc; a gift from Gilles Courtois, Biosciences and Biotechnology Institute of Grenoble, Grenoble, France). Sixteen hours after transfection, cells were stimulated with 10 ng/mL IL-1 β or 20 ng/mL TNF- α . Eight

hours after stimulation, luciferase activity was determined by using a dual luciferase assay kit (Promega, Madison, Wis).

Retroviral vector production

pRetro-DSG1 was a gift from Kathleen Green (Northwestern University, Chicago, Ill). For virus preparation, pRetro-DSG1 or blank vector was cotransfected with jetPRIME reagent (Polyplus Transfection) and packaging vectors pGag/Pol and pVSVG into HEK293T cells. Infectious retroviruses were harvested at 24, 48, and 72 hours after transfection and filtered through 0.8- μ m-pore cellulose acetate filters. Recombinant retroviruses were concentrated by means of ultracentrifugation (2 hours at 20,000g) and resuspended in Hank balanced salt solution. Viral aliquots were frozen and stored.

Lentiviral and retroviral transductions

Primary keratinocytes from a healthy control subject were seeded into 12-well plates. Twelve hours later, keratinocytes were infected with lentivirus containing (or not) DSG1 short hairpin RNA (sc-35224-V; Santa Cruz Biotechnology). Twenty-four hours after infection, keratinocytes were stimulated or not with 10 ng/mL human IL-1 β (R&D Systems). Twenty-four hours after stimulation, cells were pelleted for RNA extraction. Expression of DSG1 was assessed by using quantitative RT-PCR. Primary keratinocytes from patient 1 and a healthy control subject were seeded into 12-well plates (80,000 cells/well). Twelve hours later, keratinocytes (20% confluent) were infected with retrovirus containing (or not) the DSG1 construct. Twenty-four hours after infection, keratinocytes were stimulated with 10 ng/mL IL-1 β (R&D Systems). Lastly, 24 hours after stimulation, cells were pelleted for RNA extraction. DSG1 expression was assessed by using quantitative RT-PCR.

Reagents

Anti-FLAG antibody (diluted 1:10 000; Sigma-Aldrich, St Louis, Mo) was used as a reagent.

Light microscopy

Skin and heart biopsy specimens were fixed in 10% formalin, embedded in paraffin, and processed by using standard procedures. Three-micrometer-thick sections were stained with hematoxylin and eosin reagent and examined under LEICA DFC280 light microscopy (Leica, Buffalo Grove, Ill) at different magnifications. Images were acquired with Leica Application Suite Software.

Electron microscopy

Skin biopsy specimen was immersed in 2.5% glutaraldehyde fixative in 0.1 mol/L cacodylate buffer at pH 7.4 for 3 to 5 hours at 4°C, washed thoroughly in cacodylate buffer overnight at 4°C, and then postfixed in 1% osmium tetroxide for 1 hour at room temperature. The skin biopsy slices were then dehydrated in graded ethanol and impregnated with epoxy resin. After selection of suitable areas, semithin sections were stained with 1% toluidine blue and examined under a light microscope. Ultrathin sections were prepared and stained with uranyl acetate and lead citrate for electron microscopy (Tecnaï T12; FEI, Hillsboro, Ore).

Immunohistochemical analysis of skin and esophageal biopsy specimens

Immunohistochemical reactions were performed on 4- μ m-thick frozen tissue sections by using rabbit anti-DSG1 antibody (diluted 1:50, sc-20114; Santa Cruz Biotechnology), mouse anti-DSP I/II antibody (diluted 1:50, sc-390975; Santa Cruz Biotechnology), or sheep anti-ERBIN antibody (diluted 1:20, AF-7866; R&D Systems). Secondary antibodies were anti-rabbit Alexa Fluor 546, anti-mouse Alexa Fluor 488, and anti-sheep Alexa Fluor 488 (Life Technologies, Grand Island, NY) diluted 1:500 in 1% normal goat serum and

incubated for 1 hour at 37°C. Sections were washed with once with PBS. Coverslips were mounted with *In Situ* Mounting Medium with DAPI (Duo-link; Olink Biosciences, Uppsala, Sweden). Images were acquired and processed with an LSM700 microscope (Zeiss, Jena, Germany) and Zen Software (Zeiss). Data were quantified with ImageJ software (<https://imagej.nih.gov/ij/>). Quantifications of the ERBIN/DSG1 colocalization have been made by using a surface-based colocalization measurement on Fiji (with immunofluorescence and confocal microscopy). Data corresponded to the average of the quantification of 5 images per skin (n = 5). Data are quoted as means \pm SDs. ****P* < .001. All scale bars = 20 μ m.

Immunohistochemistry of heart biopsy specimens

Immunohistochemistry was performed on formalin-fixed, paraffin-embedded sections. After the deparaffination steps, reactions were carried out according to the automatized system Bond (A. Menarini Diagnosis system, Firenze, Italy). Staining was performed with the Menarini refine detection kit. Anti-desmoplakin 1+2 antibody (clone 65146; Progen, Heidelberg, Germany) was used.

Study approval

Clinical investigations were conducted according to Declaration of Helsinki principles and approved by the local ethics committee. Written informed consent was provided for a picture of the 3 patients appearing in the article. All patients, parents, and control subjects provided informed consent for genetic studies.

Statistical analysis

Results were expressed as the means \pm SDs. Statistical significance was determined by using unpaired 2-sample *t* tests (equal variance). All data were normally distributed, and variance was similar in groups that were compared in statistical tests. The threshold for statistical significance was set at a *P* value of less than .05.

REFERENCES

- Green H, Rheinwald JG, Sun TT. Properties of an epithelial cell type in culture: the epidermal keratinocyte and its dependence on products of the fibroblast. *Prog Clin Biol Res* 1977;17:493-500.
- Rheinwald JG, Green H. Serial cultivation of strains of human epidermal keratinocytes: the formation of keratinizing colonies from single cells. *Cell* 1975;6:331-43.
- Choi H-J, Weis WI. Crystal structure of a rigid four-spectrin-repeat fragment of the human desmoplakin plakin domain. *J Mol Biol* 2011;409:800-12.
- Samuelov L, Sarig O, Harmon RM, Rapaport D, Ishida-Yamamoto A, Isakov O, et al. Desmoglein 1 deficiency results in severe dermatitis, multiple allergies and metabolic wasting. *Nat Genet* 2013;45:1244-8.
- Has C, Jakob T, He Y, Kiritsi D, Hausser I, Bruckner-Tuderman L. Loss of desmoglein 1 associated with palmoplantar keratoderma, dermatitis and multiple allergies. *Br J Dermatol* 2015;172:257-61.
- Schlipf NA, Vahlquist A, Teigen N, Virtanen M, Dragomir A, Fismen S, et al. Whole-exome sequencing identifies novel autosomal recessive DSG1 mutations associated with mild SAM syndrome. *Br J Dermatol* 2016;174:444-8.
- Cheng R, Yan M, Ni C, Zhang J, Li M, Yao Z. Report of Chinese family with severe dermatitis, multiple allergies and metabolic wasting syndrome caused by novel homozygous desmoglein-1 gene mutation. *J Dermatol* 2016;43:1201-4.
- Dănescu S, Leppert J, Cosgarea R, Zurac S, Pop S, Baican A, et al. Compound heterozygosity for dominant and recessive DSG1 mutations in a patient with atypical SAM syndrome (severe dermatitis, multiple allergies, metabolic wasting). *J Eur Acad Dermatol Venereol* 2017;31:e144-6.
- McAleer MA, Pohler E, Smith FJD, Wilson NJ, Cole C, MacGowan S, et al. Severe dermatitis, multiple allergies, and metabolic wasting syndrome caused by a novel mutation in the N-terminal plakin domain of desmoplakin. *J Allergy Clin Immunol* 2015;136:1268-76.
- Boydin LM, Kam CY, Hernández-Martín A, Zhou J, Craiglow BG, Sidbury R, et al. Dominant de novo DSP mutations cause erythrokeratoderma-cardiomyopathy syndrome. *Hum Mol Genet* 2016;25:348-57.




FIG E1. Histopathologic and molecular features of patients 1 and 2. **A**, Histopathology of a skin biopsy specimen (patient 2) revealed acanthosis, acantholysis (lower part of the epidermis), inflammatory infiltrate (lymphocytes and histiocytes) in the dermis, and a pustula with neutrophils (*asterisk*; $\times 200$ magnification for the *inset* of Fig E1, A and B, *b*). **B**, Histopathology of heart explants (left ventricle, patient 2) showing fatty infiltration (epicardium, *asterisk*) and major fibrous infiltration (subepicardium, *arrows*, *a*; $\times 25$ magnification for Fig E1, B, *a*). Presence of dystrophic nuclei in the cardiomyocytes is shown (fibrotic areas, *arrows*, *b*). Immunohistochemical comparison of DSP expression in heart sections shows a strong and regular pattern of reactivity in the intercalated discs (control, *c*) compared with the lower and abnormally distributed pattern (patient 2, *d*). **C**, Pedigrees and sequence electropherograms of patients 1 (*a*) and 2 (*b*). **D**, Locations of H586 and S610 residues within DSP's SR6 domain (orange) at the surface of straight α -helices. The SR5 domain is shown in magenta. **E**, DSP protein consists of 3 major regions with the indicated amino acid boundaries. Close-up view of the plakin domain within the DSP N-terminal domain (*DPNT*), with colored regions representing the 4 spectrin repeats found in the crystal structure of DSP (residues 181-625). The figure was used with permission from Choi et al.^{E3} **F**, Immunoblots of DSP and DSG1 in keratinocytes from patient 1 and a control subject.




FIG E2. DSG1 inhibits NF- κ B-mediated epithelial inflammation. **A**, Relative mRNA expression of *IL8* analyzed by using quantitative RT-PCR in primary keratinocytes from patient 1 and a healthy control subject after inhibition of IKK β by ML120B. **B**, *IL6* production by keratinocytes from patient 1 and control subjects ($n = 3$). **C**, NF- κ B luciferase reporter assay in HEK293T cells transfected with 250 ng of DSP. *Inset*, Western blot analysis of DSP expression in HEK293T cells transfected with 250 ng of DSP. **D**, *IL6* and *IL8* mRNA relative expression in HEK293T cells transfected with DSG1 (250 ng) and stimulated with IL-1 β . **E**, *DSG1* mRNA relative expression in control keratinocytes infected with lentivirus expressing shDSG1 and stimulated or not with IL-1 β . AU, Arbitrary units; NS, nonstimulated. ** $P < .01$ and *** $P < .001$.




FIG E3. Expression and subcellular localization of ERBIN in the keratinocytes of patient 1. **A**, Immunofluorescence analysis of skin sections from a healthy control subject (*a-c*) and from patient 1 (*d-f*) showing a reduction in DSG1 (in red) and ERBIN (in green) staining at the plasma membrane of patient 1's keratinocytes. The 2 proteins accumulated in the cytoplasm of patient 1's keratinocytes. Scale bar = 20 μ m. Data are representative of 3 independent experiments. **B**, Quantification of ERBIN/DSG1 colocalization at the plasma membranes in skin keratinocytes from a healthy control subject and patient 1. **C**, Immunofluorescence analysis of primary keratinocytes from a healthy control subject (*a-f*) and patient 1 (*g-i*). Note the increase in DSG1 (in red) and ERBIN (in green) staining at the plasma membrane of control keratinocytes (*d-f*) after stimulation with IL-1 β . This increase was absent in patient 1's keratinocytes (*j-l*). Scale bar = 20 μ m. Data are representative of 2 independent experiments (controls, $n = 3$). **D**, Quantification of ERBIN/DSG1 colocalization at the plasma membrane of primary keratinocytes. **E**, Immunoblotting of ERBIN in keratinocytes from patient 1 and a healthy control subject. Primary keratinocytes were either stimulated with IL-1 β or not stimulated (NS). Data are shown as means \pm SDs. *** $P < .001$.

TABLE E1. Main clinical characteristics of reported patients with SAM syndrome caused by recessive mutation in the *DSG1* gene

Disease	Total patients	Past familial history	Dermatologic symptoms	Features of ectodermal dysplasia				Allergic details	Cardiac involvement	<i>DSG1</i> mutation
				Hair	Teeth	Nails	Sweating			
SAM syndrome	Two sisters	Diffuse plantar keratoderma (mother)	PPK, skin fragility, congenital ichthyosiform erythroderma	Sparse	NS	NS	NS	Severe food allergies, increased total IgE levels, eosinophilic esophagitis (1 patient)	No (1)/muscular ventricular-septal defects (1)	c.49-1G>A (homozygous) ^{E4}
	Two sisters	Focal palmar keratoderma (father)	Congenital erythroderma	Sparse	NS	NS	NS	Multiple food allergies, increased total IgE levels	No	c.1861delG (homozygous) ^{E4}
	1 (F)	Focal plantar keratoderma (mother)	PPK, atopic dermatitis since the first month of life with severe generalized flares of dermatitis	Curly	No	No	NS	Multiple allergies, increased total IgE levels	No	c.2659C>T, p.R887*, exon 15 (homozygous) ^{E5}
	Two half brothers	Mild PPK (mother)	PPK, skin erosions, psoriasiform and eczematous erythroderma in the first few months of life	No	No	No	No (1)/NS (1)	Multiple allergies, increased total IgE levels	No	c.2614delA (p.Ile872Serfs*10), exon 15 (homozygous) ^{E6}
	Two brothers and sisters	PPK (both parents)	PPK, skin erosions, congenital erythroderma	Curly and hard	No	No (1)/“affected nails” w/o precision (1)	NS	Isolated increased total IgE levels for the boy	No	c.1892-1delG/p.Gly631Glnfs*8, exon 14 (homozygous) ^{E7}
	1 (F)	PPK (father)	PPK, transient erythematous patches	Curly	No	No	No	Slight increased total IgE levels, no clinical manifestation of allergy	No	c.811_812delAC, (p.Q271Vfs*20), exon 7 + c.2100+4A>G, IVS14+4A>G, intron 14 ^{E8}

These 10 patients do not seem to have ectodermal dysplasia, even when they presented with ectodermal dysplasia features.

F, Female; NS, not specified; PPK, palmoplantar keratoderma; w/o, without.

TABLE E2. Main clinical characteristics of reported patients with SAM syndrome caused by a dominant mutation in the *DSP* gene

Disease	Total patients	Past familial history	Dermatologic symptoms	Features of ectodermal dysplasia				Allergic details	Cardiac involvement	<i>DSP</i> mutation
				Hair	Teeth	Nails	Sweating			
SAMEC syndrome	1 (M)	NS	Diffuse PPK, erythroderma from the first week of life with superficial pustulosis	Yes, hypotrichosis	Yes, hypodontia	Yes, nail dystrophy	NS	Multiple food allergies, increased total IgE levels	Normal at 6 y (clinical examination and ultrasonography)	c.1757A>C (p.His586Pro-, exon 14 (heterozygous) ^{E9}
	1 (M)	NS	PPK, erythrokeratoderma	Yes, sparse hair at birth, scalp hair was absent afterward	Yes, enamel defect, no hypodontia on primary teeth (but died at 3 y)	Yes, nail dystrophy	NS	No clinical manifestation of allergy, normal level of total IgE	Yes, marked left atrial and ventricular dilation and right ventricular dilation with an ejection fraction of 20%; patient died of heart failure at 3 y	Q616P, exon 14 (heterozygous) ^{E10}
	1 (M)		PPK, erythrokeratoderma	Yes, sparse eyebrows, eyelashes, and scalp hair	Yes, hypodontia, enamel defects	Yes, nail dystrophy	NS	No clinical manifestation of allergy, normal level of total IgE	Yes, pronounced left ventricular dilation and right atrial dilation	H618P, exon 14 (heterozygous) ^{E10}
	1 (F)		PPK, erythrokeratoderma	Yes, sparse eyebrows, eyelashes, and scalp hair	Yes, hypodontia	Yes, nail dystrophy	NS	No clinical manifestation of allergy, normal level of total IgE	Yes, a moderately dilated left ventricle with low normal systolic function	L622P, exon 14 (heterozygous) ^{E10}

These 4 patients have ectodermal dysplasia.

F, Female; M, male; NS, not specified; PPK, palmoplantar keratoderma.